GeneDx reports GUARDIAN genomic newborn screening study enrolls 30,000 infants, with 72.3% participation rate
Bitget2026/10/07 12:32GeneDx flagged new evidence supporting genomic newborn screening, with study updates set for presentation at ICoNS on Oct. 7-8 in Boston. GUARDIAN study results indicated strong enrollment, consistent performance across diverse ancestries, meaningful clinical findings, alongside existing newborn screening. Screening also surfaced actionable inherited cardiac-risk cases, prompting preventive treatment in infants, with follow-on testing identifying at-risk relatives. BRIDGES-NBS, a nationwide NIH-funded initiative, is scheduled to start enrolling this month to test multi-state rollout inside public screening programs. Program design targets early-life treatable conditions, positioning GeneDx to support broader clinical adoption if feasibility and outcomes hold. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007662968) on October 07, 2026, and is solely responsible for the information contained therein.
- GeneDx flagged new evidence supporting genomic newborn screening, with study updates set for presentation at ICoNS on Oct. 7-8 in Boston.
- GUARDIAN study results indicated strong enrollment, consistent performance across diverse ancestries, meaningful clinical findings, alongside existing newborn screening.
- Screening also surfaced actionable inherited cardiac-risk cases, prompting preventive treatment in infants, with follow-on testing identifying at-risk relatives.
- BRIDGES-NBS, a nationwide NIH-funded initiative, is scheduled to start enrolling this month to test multi-state rollout inside public screening programs.
- Program design targets early-life treatable conditions, positioning GeneDx to support broader clinical adoption if feasibility and outcomes hold.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitwise Makes Biggest XRP Purchase in October
Japan shares extend losses as rate uncertainty, geopolitical woes curb appetite
Updates with closing prices By Satoshi Sugiyama TOKYO, Oct 8 (Reuters) - Japanese shares fell more than 1% on Thursday, down for a second consecutive session, as investors paused after recent rallies, wary of the US rate outlook, higher yields and geopolitical tensions. The Nikkei 225 Index .N225 fell 1.42% to close at 69,042.11, while the broader Topix .TOPX slid 1.51% to 4,091.46. "Japanese shares had risen at a rapid pace through yesterday, and profit-taking has since picked up. That selling pressure appears to be continuing today," said Hiroki Takei, strategist at Resona Holdings. Japanese AI-related shares were subdued even after Samsung Electronics 005930.KS, the world's largest memory chipmaker, projected a nearly ninefold jump in third-quarter operating profit from the same period last year. Shares of chipmaker Rohm 6963.T lost 5.19%, the biggest percentage drag in nearly a month, while technology investor SoftBank Group 9984.T shed 4.28% and Tokyo Electron 8035.T dropped 2.48%. Concerns over US monetary policy remained in focus after Federal Reserve minutes released on Wednesday showed most participants signalling another rate hike by year-end. Market participants remained wary of French and Italian debt markets, with rising energy prices and fiscal concerns keeping sentiment fragile. Geopolitical tensions also dampened risk appetite, as increased attacks on shipping in the Gulf and the Strait of Hormuz fuelled concerns over Middle East oil supplies and pushed crude prices higher. Breadth was negative, with 165 decliners in the Nikkei 225 against 56 advancers and four unchanged. The largest percentage losers in the Nikkei were semiconductor silicon wafer supplier Sumco 3436.T, down 5.73%, followed by construction machinery maker Komatsu 6301.T, down 5.52%, and agricultural machinery and equipment maker Kubota Corporation 6326.T, down 5.42%. The largest percentage gainers were cybersecurity software company Trend Micro 4704.T, up 3.89%, followed by IT consulting firm Nomura Research Institute 4307.T, whic
Third largest since 2008! US stocks saw single-week outflows of $11 billions, technology stocks hit hardest
Last week, institutional investors significantly sold off individual stocks, resulting in a net outflow of $11.0 billion from the U.S. stock market. Funds were mainly withdrawn from the technology sector, marking the third largest single-week outflow from individual stocks in the history of Bank of America's statistics.

Google (GOOGL.US) AI pharmaceutical company Isomorphic Labs launches new financing: Raised $2.1 billions five months ago, current round aims for a $50 billions valuation
Isomorphic Labs, a DeepMind spin-off, is in talks for new financing, with its valuation potentially reaching up to $50 billions. This comes only five months after its $2.1 billions Series B funding round.